BearDownAZ,

From the Amarin trial I see they did a 5 point MACE trial and they went up to $5 billion MC with under %30 RRR (if i remember it was just 25%).

Why did we choose to do the 3 point MACE (much harder to achieve) when we could have done a 3 point MACE as a secondary endpoint and a 5 point as a primary endpoint. We excelled greatly with the 5 point in the phase 2.

Seeing as how AMARIN gained alot of MC with their succes we would have probably done the same and then have the 3 point as a backup in the secondary.

Why did we assume so much risk by doing the 3 point as primary,...? I know you suggested it was the FDA who encouraged us, but it us who are paying the costs. 

Thanks